Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Research Protocols

Date Submitted: Jun 13, 2024
Open Peer Review Period: Jun 13, 2024 - Aug 8, 2024
Date Accepted: Apr 4, 2025
(closed for review but you can still tweet)

The final, peer-reviewed published version of this preprint can be found here:

Strategy for Withdrawal of Pharmacological Treatment for Urinary Incontinence in Children (StayDry): Protocol for an Open-Label Prospective Randomized Trial

Svendsen AKM, Hagstrøm S, Kamperis K, Andersen AER, Henneberg NC, Van Batavia J, Olesen AE, Borch L

Strategy for Withdrawal of Pharmacological Treatment for Urinary Incontinence in Children (StayDry): Protocol for an Open-Label Prospective Randomized Trial

JMIR Res Protoc 2025;14:e63226

DOI: 10.2196/63226

PMID: 40633093

PMCID: 12287669

“Strategy for withdrawal of pharmacological treatment for urinary incontinence in children (StayDry): Protocol for an open-label prospective randomized trial”

  • Ann-Kristine Mandøe Svendsen; 
  • Søren Hagstrøm; 
  • Konstantinos Kamperis; 
  • Anna Elizabeth Rhode Andersen; 
  • Nanna Celina Henneberg; 
  • Jason Van Batavia; 
  • Anne Estrup Olesen; 
  • Luise Borch

ABSTRACT

Background:

To the best of our knowledge, no studies have investigated the withdrawal strategy of pharmacological treatment with solifenacin and/or mirabegron in children diagnosed with urinary incontinence that have achieved continence on pharmacotherapy.

Objective:

The primary objective is to investigate if abrupt withdrawal versus gradual withdrawal of pharmacotherapy (solifenacin and/or mirabegron) influences the risk of recurrence of incontinence, assessed by a self-reported online 14-day calendar of incontinence episodes.

Methods:

Children aged 5-14 years diagnosed with urinary incontinence, treated with pharmacotherapy of solifenacin and/or mirabegron and ready for withdrawal will be randomized 1:1 to either abrupt or gradual withdrawal, according to the medical treatment that the child is receiving. The primary outcome measure is recurrence of incontinence after withdrawal 1 month after initiation of withdrawal of the physician prescribed medication, assessed by a self-reported online 14-day calendar of incontinence episodes. Additionally, recurrence of incontinence after 3, 6 and 12 months after initiation of withdrawal will be measured.

Results:

Recruitment began ultimo May 2024 and will continue until 216 patients are included, which is expected by December 2027. As of January 2025, 20 participants are included.

Conclusions:

The results are expected to influence the withdrawal strategy of pharmacological treatment with solifenacin and/or mirabegron in children with daytime urinary incontinence. Clinical Trial: CTIS: EU CT 2023-510280-35-00 ClinicalTrials.gov ID: NCT06465576


 Citation

Please cite as:

Svendsen AKM, Hagstrøm S, Kamperis K, Andersen AER, Henneberg NC, Van Batavia J, Olesen AE, Borch L

Strategy for Withdrawal of Pharmacological Treatment for Urinary Incontinence in Children (StayDry): Protocol for an Open-Label Prospective Randomized Trial

JMIR Res Protoc 2025;14:e63226

DOI: 10.2196/63226

PMID: 40633093

PMCID: 12287669

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.